Immune
Therapeutics Inc Announces Publication of Peer
Reviewed Scientific Paper Describing
Low-Dose Naltrexone
(LDN): A Promising Treatment in Immune-Related
Diseases and Cancer
Therapies.
Orlando, FL -- July 24, 2018
-- InvestorsHub NewsWire -- Immune Therapeutics, Inc.
(OTCQB:IMUN)
("Immune" "IMUN" or the "Company"), a clinical late stage
biopharmaceutical company focused on the development of therapies
for the treatment of autoimmune diseases, inflammatory diseases,
cancer and HIV/AIDS, is pleased to announce the
publication of a
peer reviewed scientific paper describing LDN as a promising treatment
in immune related disease and cancer therapies as identified in the lab by Dr.
Fengping Shan, IMUN's Chief Scientific
Officer.
The scientific paper by
Fengping and Griffin et al.
entitled, Low-dose naltrexone (LDN): A
promising treatment in immune-related diseases and cancer
therapies was recently published in
the online edition of the
International
Immunopharmacology
(
https://www.ncbi.nlm.nih.gov/pubmed/29885638)
In this paper, the authors
describe and analyze naltrexone, a non-selective antagonist of
opioid receptors, is mainly used as rehabilitation therapy for
discharged opiate addicts to eliminate addiction in order to
maintain a normal life and prevent or reduce relapse. In recent
years, there have been some novel and significant findings on the
off-label usage of naltrexone. Within a specific dosage window, LDN
can act as an immunomodulator in multiple autoimmune diseases and
malignant tumors as well as alleviate the symptoms of some mental
disorders. The results of increasing studies indicate
that
LDN exerts its
immunoregulatory activity by binding to opioid receptors in or on
immune cells and tumor cells. These new discoveries indicate that
LDN may become a promising immunomodulatory agent in the therapy
for cancer and many immune-related diseases. In this article, we
review the pharmacological functions and mechanisms of LDN as well
as its clinical therapeutic potential as revealed by our team and
other researchers.
Until now, no review specic
focused on the immunoregulatory functions of LDN has been reported.
In this article, we provide a comprehensive summary of the
immune-related pharmacological functions and potential mechanisms
of LDN.
To our knowledge, LDN could
modulate the immune system function of the body to resist an
abnormal immune response, and it has been widely accepted by
patients with MS, IBD such as CD and many types of malignant
tumors. Successful reports of patients with bromyalgia, ALS
and type 1
diabetes treated with LDN are increasing. Future studies and
clinical work are warranted to conrm the role of LDN in the
treatment of immune-related diseases.
LDN may be considered as a
novel immunomodulator and tumor biotherapy agent, which is
routinely recommended for people with autoimmune diseases and
cancer. At the same time, researchers also found that LDN could
control appetite and the intake of high-sugar and high-fat foods
and that the eect and mechanism of LDN on body weight control were
of great value. Moreover, it is believed that LDN will have more
novel dosage forms, such as passive transdermal delivery, liquid
nasal spray and sustained-release preparations ,
in the near
future.
Although there are many
advantages of LDN therapy, such as low cost, low adverse reaction,
high safety, easy availability and better compliance, some issues
are still worth noting. Since LDN is thought to play a role in the
regulation of inammatory mediators and the upregulation of
endogenous opioid receptors, physicians should be alert to patients
who have prior chronic use of LDN in pain management when using
exogenous opioids in order to prevent hypersensitivity to exogenous
opioids.
Additionally, patient-funded
research on LDN for the treatment of multiple sclerosis is good
news for both doctors and patients, but attention should be paid to
issues such as program reviews and conicts of
interest.
Noreen Griffith is currently
attending the 22nd International AIDS Conference
(AIDS 2018), taking place in
Amsterdam,
this week (July
23-27).
As well, as a testament to
the work being done, Ms. Griffin has been invited to attend the
SCON Summit on HIV and AIDS. Below please find a copy of the
invitation.
Dear. Noreen
Griffin,
Hope you are doing
well.
We would like to solicit your
gracious presence as a Speaker at the upcoming "SCON Summit on HIV
and AIDS" which is scheduled from December 06-07, 2018 at Las
Vegas, USA.
Our research team had a
glance on one of your publication titled "Low-dose naltrexone
(LDN): A promising treatment in immune-related diseases and cancer
therapy" which is very impressive. We appreciate if you could
deliver your lecture as a Speaker on the same.
Kindly have a glance for more
information: http://hivaids.scholarenaconferences.com
We
believe your
voice would be a critical addition to the SCON HIV AIDS-2018 stage.
Please let us know you are ready with your abstract. Kindly submit
your abstract as much as possible.
Thank you for reading, and we
very much look forward to hearing from you.
XXXXX
ABOUT IMMUNE
THERAPEUTICS, INC.
Immune Therapeutics Inc. is a
late stage clinical stage biopharmaceutical company focused on the
development and commercialization of our highly innovative
immunotherapies. IMUN is a biotechnology company developing
T-Activation immunotherapies to achieve immunomodulation in
patients with autoimmune and inflammatory disease and cancer and
infectious diseases.
Stimulating the body's immune
system remains one of the most promising approaches in the
treatment of Cancers, HIV, Autoimmune Diseases, inflammatory
conditions and other chronic infectious diseases.
Forward-Looking Statements
This release may contain
forward-looking statements. Actual results may differ
from those projected due to a number of risks and uncertainties,
including, but not limited to, the possibility that some or all the
matters and transactions considered by the Company may not proceed
as contemplated, and by all other matters specified in the
Company's filings with the Securities and Exchange
Commission. These statements are made
based upon current expectations that are subject to risk and
uncertainty. The Company does not
undertake to update forward-looking statements in this news release
to reflect actual results, changes in assumptions or changes in
other factors affecting such forward-looking
information. Assumptions and other
information that could cause results to differ from those set forth
in the forward-looking information can be found in the Company's
filings with the Securities and Exchange Commission (www.sec.gov),
including its recent periodic reports.
888-613-8802
http://www.immunetherapeutics.com/
http://www.immunetherapeutics.com/